The kinetics and cytotoxicity of cisplatin and its monohydrated complex

Cancer Letters

Volumn 132, Issue 1-2, 1998, Pages 175-180

  Yachnin, Jeffrey R ^a   Wallin, Inger ^a   Lewensohn, Rolf ^a,b   Sirzén, Florin ^a   Ehrsson, Hans ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b Swedish Radiation Protection Authority   (Sweden)

Author keywords

Cisplatin; Cytotoxicity; Hydrolysis products; Kinetics

Indexed keywords

CHLORIDE ION; CISPLATIN; CISPLATIN DERIVATIVE; GRAPHITE; LEDERPLATIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DETERMINATION; DRUG ISOLATION; DRUG STABILITY; HUMAN; HUMAN CELL; LIQUID CHROMATOGRAPHY; LUNG SMALL CELL CANCER; PH; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; CISPLATIN; CULTURE MEDIA; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; HYDROGEN-ION CONCENTRATION; KINETICS; TOXICITY TESTS; TUMOR CELLS, CULTURED;

EID: 0032561451     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(98)00175-X     Document Type: Article

References (27)

1. Andersson A., Hedenmalm H., Elfsson B., Ehrsson H. Determination of the acid dissociation constant for cis-diammineaquachloroplatinum(II) ion. A hydrolysis product of cisplatin. J. Pharm. Sci. 83:1994;859-862.
2. Andersson A., Ehrsson H. Determination of cisplatin and cis-diammineaquachloroplatinum(II) ion by liquid chromatography using post-column derivatization with diethyldithiocarbamate. J. Chromatogr. B. 652:1994;203-210.
3. Andersson A., Fagerberg J., Lewensohn R., Ehrsson H. Pharmacokinetics of cisplatin and its monohydrated complex in man. J. Pharm. Sci. 85:1996;824-827.
4. Atema A., Buurman K.J.H., Noteboom E., Smets L.A. Potentiation of DNA-adduct formation and cytotoxicity of platinum-containing drugs by low pH. Int. J. Cancer. 54:1993;166-172.
5. 195Pt NMR kinetic and mechanistic studies of cis- and trans-diamminedichloroplatinum (II) binding to DNA. J. Am. Chem. Soc. 112:1990;6860-6871.
6. Bergh J., Larsson E., Zech L., Nilsson K. Establishment and characterization of two neoplastic cell lines (U-1285 and U-1568) derived from small-cell carcinoma of the lung. Acta Pathol. Microbiol. Immunol. Scand. 90:1982;149-158.
7. Croix B.S., Rak J.W., Kapitain S., Sheehan C., Graham C.H., Kerbel R.S. Reversal by hyaluronidase of adhesion-dependent multicellular drug resistance in mammary carcinoma cells. J. Natl. Cancer Inst. 88:1996;1285-1296.
8. Daley-Yates P.T., McBrien D.C.H. The inhibition of renal ATPase by cisplatin and some bio-transformation products. Chem.-Biol. Interact. 40:1982;325-334.
9. Daley-Yates P.T., McBrien D.C.H. Cisplatin metabolites in plasma, a study of their pharmacokinetics and importance in the nephrotoxic and antitumour activity of cisplatin. Biochem. Pharmacol. 33:1984;3063-3070.
10. Eastman A. Activation of programmed cell death by anticancer agents: cisplatin as a model system. Cancer Cells. 2:1990;275-280.
11. Ehrsson H., Wallin I., Andersson A., Edlund P.O. Cisplatin, transplatin, and their hydrated complexes: separation and identification using porous graphitic carbon and electrospray ionization mass spectrometry. Anal. Chem. 67:1995;3608-3611.
12. Gately D.P., Howell S.B. Cellular accumulation of the anticancer agent cisplatin: a review. Br. J. Cancer. 67:1993;1171-1176.
13. 2 gradients in solid tumors in vivo: high-resolution measurements reveal a lack of correlation. Nat. Med. 3:1997;177-182.
14. Herman T.S., Teicher B.A., Collins L.S. Effect of hypoxia and acidosis on the cytotoxicity of four platinum complexes at normal and hyperthermic temperatures. Cancer Res. 48:1988;2342-2347.
15. Jennerwein M., Andrews P.A. Drug accumulation and DNA platination in cells exposed to aquated cisplatin species. Cancer Lett. 81:1994;215-220.
16. Jennerwein M., Andrews P.A. Effect of intracellular chloride on the cellular pharmacodynamics of cis-diamminedichloroplatinum(II). Drug Metab. Dispos. 23:1995;178-184.
17. Kohl H.H., Friedman M.E., Melius P., Mora E.C., McAuliffe C.A. Enhanced inhibition of both cellular protein synthesis and malate dehydrogenase by aged aquoplatinum (II) complexes. Chem.-Biol. Interact. 24:1979;209-215.
18. Larsson R., Nygren P. A rapid fluorometric method for semiautomated determination of cytotoxicity and cellular proliferation of human tumor cell lines in microculture. Anticancer Res. 9:1989;1111-1120.
19. Ormerod M.G., O'Neill C., Robertson D., Kelland L.R., Harrap K.R. cis-Diamminedichloroplatinum(II)-induced cell death through apoptosis in sensitive and resistant human ovarian carcinoma cell lines. Cancer Chemother. Pharmacol. 37:1995;463-471.
20. O'Neill C.F., Orr R.M., Kelland L.R., Harrap K.R. Comparison of platinum (Pt) binding to DNA and removal of total Pt adducts and inter-strand cross-links in three human ovarian carcinoma cell lines sensitive and resistant to cisplatin. Cell Pharmacol. 2:1995;1-7.
21. Rosenberg B., Van Camp L., Trosko J.E., Mansour V.H. Platinum compounds: a new class of potent antitumour agents. Nature. 222:1969;385-386.
22. Scanlon K.J., Safirstein R.L., Thies H., Gross R.B., Waxman S., Guttenplan J.B. Inhibition of amino acid transport by cis-diamminedichloroplatinum (II) derivatives in L1210 murine leukemia cells. Cancer Res. 43:1983;4211-4215.
23. Segal E., Le Pecq J.-B. Role of ligand exchange processes in the reaction kinetics of the antitumor drug cis-diamminedichloroplatinum(II) with its targets. Cancer Res. 45:1985;492-498.
24. Sherman S.E., Lippard S.J. Structural aspects of platinum anticancer drug interactions with DNA. Chem. Rev. 87:1987;1153-1181.
25. Shirazi F.H., Molepo J.M., Stewart D.J., Ng C.E., Raaphorst G.P., Goel R. Cytotoxicity, accumulation, and efflux of cisplatin and its metabolites in human ovarian carcinoma cells. Toxicol. Appl. Pharmacol. 140:1996;211-218.
26. Speelmans G., Sips W.H.H.M., Grisel R.J.H., Staffhorst R.W.H.M., Fichtinger-Schepman A.M.J., Reedijk J., de Kruijff B. The interaction of the anti-cancer drug cisplatin with phospholipids is specific for negatively charged phospholipids and takes place at low chloride ion concentration. Biochim. Biophys. Acta. 1283:1996;60-66.
27. Tannock I.F., Rotin D. Acid pH in tumors and its potential for therapeutic exploitation. Cancer Res. 49:1989;4373-4384.